|The Company founded in Kobe, Japan
Mikage Plant established at Higashinada-ku, Kobe
|Development of purification method of Urokinase
|Research Laboratories established at Higashinada-ku, Kobe
|Manufacture of Urokinase product and bulk approved
|Import of human Growth Hormone (hGH) approved in Japan
|Seishin Plant established at Nishi-ku, Kobe
Research Institute established at Nishi-ku, Kobe
|IPO (listed on the over-the-counter stock market in Japan)
|Manufacture of recombinant hGH product, Growject® Inj. 4IU, approved
Research Laboratories established in northwest Kobe
|Manufacture of Ulinastatin bulk substance approved
|Listed on the Second Section of the Osaka Securities Exchange
|Alliance established with Mochida Pharmaceutical Co., Ltd. for supply of urine-derived products.
|Alliance established with Sumitomo Pharmaceuticals Co., Ltd. (current Dainippon Sumitomo Pharmaceuticals Co., Ltd.) for co-marketing of Growject® Inj. 4IU
Manufacture of Macrophage Colony Stimulating Factor, Leucoprol®, started
Marketing approval of Growject® 8mg
Growject® approval expanded for Turner indication
|Kobe Plant established in northwest Kobe
Growject® 8mg and Growject Pen launched
|Alliance established with Osiris Therapeutics, Inc. (USA) for its technology on the use and manufacture of human mesenchymal stem cells
|Murotani Plant established at northwest Kobe
|Growject® approval expanded for adult growth hormone deficiency
|Marketing approval of “Epoetin alfa BS Inj. JCR” obtained in Japan for treatment of renal anemia
|Listed on the Second Section of the Tokyo Stock Exchange
|Growject® approval expanded for short stature associated with small for gestational age
|Kobe API Plant established at northwest Kobe
Listed on the First Section of the Tokyo Stock Exchange
|Japanese corporate name changed to "JCRファーマ"
|Marketing approval of TEMCELL® HS Inj., The first Allogeneic Regenerative Medicine in Japan
|Clinical Trial Material Manufacturing Center and Cell Processing Center established at northwest Kobe
Marketing approval for a new liquid formulation of Growject®
|Business and Capital Alliance agreement conducted with MEDIPAL HOLDINGS CORPORATION
|JCR USA, Inc. established
Marketing Approval of “Agalsidase Beta BS I.V. Infusion JCR” for Fabry disease
|Marketing Approval of “Darbepoetin Alfa BS Injection JCR”, a Long-Acting Erythropoiesis-Stimulating Agent.
|Acquire ArmaGen, Inc.
JCR DO BRASIL FARMACÊUTICOS IMPORTAÇÃO E EXPORTAÇÃO LTDA. began business activities.
|Bioresearch Center has initiated operation at northwest Kobe
Marketing Approval of “IZCARGO®” for Mucopolysaccharidosis type II
Transition to the Prime Market in the Tokyo Stock Exchange New Market Segments
JCR Europe B.V. began business activities.
AlliedCel Corporation established
Kobe Science Park Center established at northwest Kobe